ENTITY
YiChang HEC ChangJiang Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical (1558 HK)

137
Analysis
Health Care • China
YiChang HEC ChangJiang Pharmaceutical develops, manufactures, and sells pharmaceutical products, focusing on anti-viral, endocrine and metabolic, and cardiovascular diseases. Key products include Kewei (oseltamivir phosphate), Oumeining (telmisartan), and Ertongshu (benzbromarone). The company was founded in 2001 and is headquartered in Dongguan, China.
more
•10 Aug 2025 06:15

(Mostly) Asia-Pac M&A: Technopro, Infomedia, Kolon Mobility, Iress, HKBN, Furukawa Battery

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
531 Views
Share
bullish•Topcon Corp
•03 Aug 2025 06:15

(Mostly) Asia-Pac M&A: Topcon, Joy City, Hogy Medical, Nihon Chouzai, Piedmont Lithium, Pacific Ind.

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
629 Views
Share
bullish•Topcon Corp
•01 Aug 2025 06:15

(Mostly) Asia M&A, July 2025 Wrap: Pacific Industrial, Johns Lyon, TalkMed, DD Group, Hanil Cement

For the month of July, 6 new deals were discussed on Smartkarma with an overall deal size of just ~US$4bn. The average premium for the new deals...

Logo
563 Views
Share
bullish•MAC Copper
•31 Jul 2025 11:53

MAC Copper (MAC AU/MTAL US): 29th August Vote On Harmony's Offer

Both legs have the same gross/annual. spreads of 1.5%/7.9%, assuming early Oct payment. There will be nominal costs to be netted off the CDI...

Logo
452 Views
Share
•30 Jul 2025 11:59

PointsBet (PBH AU): Either Betr Pulls A Rabbit Out Of The Hat, Or Walks

I can see Mixi waiving the acceptance condition and declaring term unconditional. Trading at terms. If in, sell here. If not in, avoid unless...

Logo
395 Views
Share
x